Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version -refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.
INTRODUCTION
Chronic heart failure (HF) is associated with an increase in pulmonary capillary pressure and wall tension secondary to the rise in left ventricle (LV) filling pressure consistent with a failing LV (1) . Additionally, it has been shown that a chronic increase in adrenergic drive, as occurs with HF, elicits a down-regulation of the receptors central to lung fluid removal mechanisms (2) (3) (4) . In combination, it is possible that the aforementioned changes in the pulmonary system associated with HF may conspire to increase fluid flux across the pulmonary vasculature while impairing fluid clearance from the alveoli and interstitial space, thus making HF patients more susceptible lung fluid accumulation relative to their healthy counterparts. While pulmonary congestion, a key component of which is a significant increase in lung fluid, is a hallmark of acute decompensation in heart failure (5-7), whether stable HF patients exhibit increased extravascular lung fluid remains controversial with some (8) but not all (9) reporting an increase in lung water content in HF patients. Moreover, the role of alterations in lung -adrenoreceptor system mediated fluid clearance mechanisms in the pulmonary edema associated with HF is unclear.
Accordingly, in the present study we aimed to determine 1) whether stable HF patients with reduced ejection fraction (HFrEF) have elevated lung fluid compared to their healthy age and sex matched counterparts, and 2) the effect of an acute inhaled 2 -adrenergic receptor agonist on lung fluid balance in stable HFrEF patients.
MATERIALS AND METHODS

Participants and ethical approval
Twenty-two adult patients with a history of heart failure with reduced ejection fraction (HFrEF) and 18 healthy age-and sex-matched controls volunteered to participate in the study ( Table 1 ). The patients recruited for the study were required to meet the following criteria: 1) ≥1 y history of known HF, 2) ejection fraction of ≤40%, 3) New York Heart Association (NYHA) functional class I, II or III, 4) stable symptoms (i.e. receiving optimal medication and have had no change in disease status or medication) for >3 months, 5) free of uncontrolled systemic hypertension, anemia, or other comorbidities (e.g., COPD), 6 ) not pacemaker dependent, and 7) a BMI <36. The age-matched controls were recruited from the surrounding community and were current nonsmokers (past 15 years) with no history of cardiac or pulmonary disease. Each participant gave written informed consent after being provided a detailed description of the study requirements. The experimental procedures were approved by the Mayo Clinic
Institutional Review Board and were performed in accordance with the Declaration of Helsinki.
Experimental procedures
The experimental procedures were conducted during two separate laboratory visits separated by no longer than 1 week. At the first visit, complete blood count was assessed to rule out anemia before pulmonary function was assessed via body plethysmography (MedGraphics Elite Series Plethysmograph, Medical
Graphics Corporation, St. Paul, MN, USA) according to standard procedures (10) . During the second session, albuterol, a short acting 2 -adrenergic receptor agonist, was administered at a dilution of 2.5 mg per 3 ml of saline using a nebulizer for 15 minutes in each participant. Pulmonary function, lung diffusing capacity for carbon monoxide (DLCO) and nitric oxide (DLNO), alveolarcapillary membrane conductance (Dm CO ) and pulmonary capillary blood volume (Vc) were assessed before and within 30 min after albuterol administration.
Similarly, lung density and lung tissue volume (V tis ) were measured before and within 30 min post-albuterol via chest CT imaging.
Lung diffusing capacity
DLCO, DLNO, Dm CO and Vc were assessed by simultaneously measuring the disappearance of CO and NO using a rebreathe technique, as we have described previously (11, 12). Participants sat upright and breathed through a two-way switching valve that was connected to a pneumotachometer, a mass spectrometer (Marquette 1100 Medical Gas Analyzer, Perkin-Elmer, St. Louis, MO) and a NO analyzer (Sievers 280i NOA, Sievers, Boulder, CO). The inspiratory port of the switching valve was set to either room air or a 5-L anesthesia bag filled with 0.3% CO (C 18 O), 40 parts per million (ppm) NO (diluted in the bag immediately before each rebreathe maneuver from an 800 ppm gas mixture), 35% O 2 and N 2 balance. The total volume of gas in the anesthesia bag was determined by the resting tidal volume of each participant. For each rebreathe maneuver, the participants breathed normally on room air for 4-5 breaths before, at the end of a normal expiration, they were switched to the rebreathe bag and told to "nearly empty the bag" with each inspiration for 10-12 consecutive breaths at a breathing frequency of 32 breaths per min. Each participant performed the rebreathe maneuver in triplicate before and within 30 min after administration of nebulized albuterol. DLCO, DLNO, Dm CO and Vc were computed using custom analysis software.
Lung tissue volume & lung density via computed tomography
All CT scans were performed using the same scanner (GE LiteSpeed Spiral CT A histogram analysis of picture elements within the lung tissue was performed to obtain mean lung density in HU and tissue volume by summation of each voxel among all elements in the lung fields.
Estimation of extravascular lung water
The parenchymal attenuation assessed by CT (i.e. tissue volume, Vtis) includes lung tissue, blood and water. By combining our CT derived measure of tissue volume and our measure of Vc from the lung diffusing capacity maneuvers (12),
we were able to estimate the volume of extravascular lung water (EV LW ) as:
where, EVLW is extravascular lung water in ml, Vtis is tissue volume in ml determined via CT, and Vc is pulmonary capillary blood volume in ml assessed via our CO and NO rebreathe technique.
Albuterol administration
Using a nebulizer, albuterol (a short acting 2 -AR agonist) was administered at a dilution of 2.5 mg/3ml of saline for ~15 min during tidal breathing in each participant. Heart rate (HR) and cardiac rhythm were measured via a 12-lead ECG throughout albuterol administration. Similarly, arterial oxygen saturation (SaO 2 ) was monitored continuously during albuterol administration using a pulse oximeter (Nellcor N-595, Tyco Healthcare Group, Nellcor Puritan Bennett Division, Pleasanton, CA, USA) and a forehead sensor. Manual blood pressure and the rating of perceived dyspnea were obtained before albuterol administration and at two minute intervals thereafter until 5 min post-albuterol. 
Statistical analyses
Independent samples t-test was
RESULTS
Participant characteristics and pulmonary function measurements are shown in Table 1 .
Lung fluid balance in HFrEF vs. healthy control subjects
Baseline pre-albuterol measures of DLCO, Dm CO , Vc, lung density, Vtis, and EVLW are shown in Table 2 . Pre-albuterol administration, group mean DLCO (P = 0.037) and Vc (P = 0.003) were greater in control subjects compared HFrEF patients; there was no such difference in Dm CO between subject groups ( Table   2 ). Baseline pre-albuterol group mean lung density (P < 0.001), Vtis (P = 0.041) and EVLW (P = 0.015) were greater in HFrEF patients compared to healthy control subjects (Table 2 ). These data suggest that lung fluid is elevated in stable
HFrEF patients relative to healthy subjects.
Effect of 2 -AR stimulation in HFrEF and healthy controls
There was little/no change in either HR or blood pressure from before to immediately after albuterol administration in the HFrEF patients (HR 65 ± 9 vs.
69 ± 11 bpm, P = 0.129; MAP 92 ± 8 vs. 95 ± 7 mmHg, P = 0.098). Similarly, no evidence of cardiac arrhythmia was observed in any participant during albuterol administration. Albuterol administration had no effect on FVC, but caused an increase in FEV 1 , FEF 25-75% and IC in both the control subjects and HFrEF patients (Table 3) . DLCO, Dm CO , Vc and Dm CO /Vc were not different from before to after albuterol administration in neither the control subjects nor the HFrEF patients ( Figure 1 ). Albuterol administration did, however, cause a significant reduction in Vtis in both the healthy control subjects and the HFrEF patients (control: −2.8 ± 4.9%, P = 0.029; HFrEF: −4.6±7.8%, P =0.010) ( Figure 2 ). Similarly, there was a significant reduction in EVLW from before to after albuterol administration in both the control subjects and the HFrEF patients (control: −3.0 ± 5.7%, P = 0.045; HFrEF: −4.6±8.8%, P = 0.018) (Figure 2 ).
There was a trend towards an inverse relationship between baseline values of Vtis, EVLW and Dm CO /Vc ratio and the magnitude of the change in these variables from before to after albuterol in both the control subjects and the HFrEF patients; however, these relationships were statistically significant for EVLW and Dm CO /Vc ratio in the HFrEF patients only (Figure 3 ). These data may suggest that stimulation of the 2 -ARs via nebulized albuterol administration promoted a greater degree of lung fluid clearance in individuals with the greatest evidence lung fluid at baseline.
DISCUSSION
Main findings
The main findings of the present study were: 1) before albuterol administration, lung density, lung tissue volume (Vtis) and extravascular lung water (EVLW) were greater in the HFrEF patients compared to the healthy control subjects, 2) lung diffusing capacity for carbon monoxide (DLCO) and pulmonary capillary blood volume (Vc) were greater in control subjects compared to the HFrEF patients before albuterol administration, 3) albuterol administration caused a ~3
to 5% reduction in Vtis and EVLW in healthy control subjects and HFrEF patients, and 4) there was a trend towards an inverse relationship between baseline values of Vtis, EVLW and Dm CO /Vc ratio and the magnitude of the change in these variables from before to after albuterol in both the control subjects and the HFrEF patients; however, this relationship was statistically 
Why is lung fluid increased in stable HF?
It is well known that pulmonary congestion, a key component of which is a significant increase in lung fluid, is a common consequence of acute decompensation in HF (5-7). However, it has remained somewhat controversial whether stable HF patients exhibit elevated lung fluid volume (8, 9) , with chronic HF patients often appearing to "resist" pulmonary edema (24) . Indeed, in clinical practice it is often observed that patients with severe HF lack pulmonary rales on examination or alveolar edema on chest x-ray. Theoretically, the increase in pulmonary capillary hydrostatic pressure and wall tension due to the rise in LV filling pressure consistent with a failing LV (1) combined with downregulation of the receptors that are central to lung fluid removal mechanisms (2-4) secondary to a chronic increase in adrenergic drive should serve to make HF patients more susceptible to lung fluid accumulation relative to their healthy counterparts. However, it has also been shown that pulmonary microvascular permeability is decreased in severe HF patients, which would be expected to protect such patients from pulmonary edema (24) . Presently, we found that lung fluid is elevated in stable HFrEF patients relative to healthy subjects (Table 2) .
These data perhaps suggest that, while somewhat preventative, the reduction in pulmonary microvascular permeability often observed in stable HFrEF patients does not fully protect against an increase in extravascular lung water in this population.
Clinical implications
Recently, we have reported that CT derived measures of large airway wall thickness and luminal area are not different in healthy control subjects relative to stable HFrEF patients (27) . In combination with the findings of the present study, data from our laboratory suggest that stable, well compensated HFrEF patients have evidence of elevated lung fluid volume but not substantial large airway edema and/or engorgement relative to their healthy age and sex matched counterparts. Although the exact clinical ramifications of such an accumulation of lung fluid in these patients are unclear, it is possible that interstitial lung edema plays a role in abnormal pulmonary gas exchange and exaggerated ventilatory response to exercise associated with HF. HF is of course a complex disease and much of the impaired pulmonary gas exchange and hyperventilatory response to exercise in HF patients has been associated with pulmonary vascular dysfunction (28, 29) , skeletal muscle dysfunction (30, 31) , early onset of metabolic acidosis (32), heightened chemosensitivity, and exaggerated afferent signals from exercising muscles (30) . However, in animal models, it has been demonstrated that artificial induction of pulmonary congestion causes a rapid shallow breathing pattern secondary to stimulation of pulmonary C-fibers (33).
In addition, acute fluid loading in otherwise healthy humans has been shown to elicit a less efficient hyperventilatory response to incremental exercise (34). Data are presented as group mean ± SD or n (%). BMI, body mass index; BSA, body surface area; ISC, ischemic; IDC, idiopathic dilated cardiomyopathy; HFrEF, heart-failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; ACE, angiotensin converting enzyme; FVC, forced vital capacity; FEV 1 , forced expiratory volume in 1 s; PEF; peak expiratory flow rate; FEF 25-75% , forced expiratory flow at 25-75% of FVC; IC, inspiratory capacity; DLCO, lung diffusing capacity for carbon monoxide; V A , alveolar volume. P-values, group mean control vs. group mean HF. Table 2 . Baseline (i.e. pre-albuterol) measures of cardiovascular function, lung diffusing capacity and indices of lung fluid balance in heart-failure patients with reduced ejection fraction (HFrEF) and healthy control subjects. Table 3 . Measures of pulmonary function before and after albuterol administration in heart-failure patients with reduced ejection fraction (HFrEF) and healthy control subjects.
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